Cipla Q4 net profit slumps 55% YoY to Rs 555 crore, full-year PAT down 26%

Mumbai: Pharma major Cipla reported a 55% year-on-year decline in consolidated net profit for the quarter ended March at ₹555 crore, while total income from operations fell 3% to ₹6,541 crore For FY26, revenue rose 2% year-on-year to ₹28,163 crore, while profit after tax declined 26% to ₹3,879 crore.

The board recommended a final dividend of ₹13 per equity share of face value ₹2 for the financial year ended March.

Also read: Cohance Lifesciences shares skyrocket 20% on hiring former Cipla CEO Umang Vohra


"We continue to make considerable progress across our focused markets," MD and global CEO Achin Gupta said. "Key therapies in branded prescription business delivered robust double-digit growth, trade generics business sustained the strong growth momentum and anchor brands of consumer health business maintained leadership position."